New Finding: Overactive Mitochondria Are Responsible for Twenty Percent of Glioblastoma Brain Cancers

Neuroscience News recently carried an article heralding reports of researchers' finding that upwards of twenty percent of lethal glioblastoma brain cancers may be treatable by newly developed drugs. Currently, the…

Continue Reading New Finding: Overactive Mitochondria Are Responsible for Twenty Percent of Glioblastoma Brain Cancers

A Father is Asking for Worldwide Birthday Cards for His Seven-Year-Old Daughter Lyla Who Is Scheduled for her 10th Brain Operation

  An article in the Hartlepool Mail announced that Lyla O’Donovan, her parents, and her four brothers and sisters will be celebrating Lyla’s seventh birthday on November 28th, 2019 at…

Continue Reading A Father is Asking for Worldwide Birthday Cards for His Seven-Year-Old Daughter Lyla Who Is Scheduled for her 10th Brain Operation
Recent Study Confirms Validity of the Therapeutic Target of an Experimental Brain Cancer Drug
sbtlneet / Pixabay

Recent Study Confirms Validity of the Therapeutic Target of an Experimental Brain Cancer Drug

According to a story from BioSpace, Oncotelic, Inc., recently announced the publication of a study in the Journal of Clinical Research in Pediatrics. This study appears to back up the therapeutic…

Continue Reading Recent Study Confirms Validity of the Therapeutic Target of an Experimental Brain Cancer Drug
Biotech Companies Team Up to Launch MapKure, a New Joint Venture to Develop Small Molecule Anticancer Drug
rawpixel / Pixabay

Biotech Companies Team Up to Launch MapKure, a New Joint Venture to Develop Small Molecule Anticancer Drug

According to a press release from BeiGene, the Company and SpringWorks Therapeutics have launched MapKure, LLC — a new, jointly-operated venture owned by both partners. MapKure was founded to develop…

Continue Reading Biotech Companies Team Up to Launch MapKure, a New Joint Venture to Develop Small Molecule Anticancer Drug

The FDA’s Director of the Center for Drug Evaluation Discusses Accelerated Approvals

  In the mid-1980s the FDA was criticized for being slow in approving new drugs. In fact, a commission was formed as a result of the mounting criticism. Janet Woodcock,…

Continue Reading The FDA’s Director of the Center for Drug Evaluation Discusses Accelerated Approvals